Adimmune (TPE:4142) Beta: 0.0420 (As of Jun. 26, 2026)


TPE:4142 Adimmune Corp TPE:4142
55 GF Score
Price NT$16.80
GF Value NT$25.40
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Adimmune Beta?

Adimmune TPE:4142 -1.75% 55 Beta is 0.0420 as of Jun. 26, 2026. GuruFocus rates TPE:4142 with a GF Score™ of 55/100 and a GF Value™ of NT$25.40 (Possible Value Trap). The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Adimmune's Beta is 0.0420.


Adimmune  (TPE:4142) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Adimmune Beta Related Terms


Adimmune Beta Historical Data

* Premium members only.

The historical data trend for Adimmune's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adimmune Beta Chart

Adimmune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.42 0.61 0.46 0.00

Adimmune Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.00 0.00 0.00 0.00

TPE:4142 vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Adimmune's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adimmune Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adimmune's Beta distribution charts can be found below:

* The bar in red indicates where Adimmune's Beta falls into.


TPE:4142
55GF Score
Adimmune Corp TPE:4142
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adimmune Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.0420 mean?
Adimmune (TPE:4142) has a Beta of 0.0420 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Adimmune and its competitors.
Is Adimmune's Beta too high?
Adimmune's current Beta is 0.0420. Overall, Adimmune has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Adimmune's Beta compare to VRTX and REGN?
Adimmune's Beta of 0.0420 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Adimmune and its competitors. Adimmune's current Beta is 0.0420. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adimmune stock overvalued right now?
Based on GuruFocus' analysis, Adimmune (TPE:4142) is currently considered Possible Value Trap. The stock's GF Value™ is NT$25.40, compared to a current price of NT$16.80 — trading 33.9% below its estimated fair value. The current Beta is 0.0420. Adimmune's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Adimmune (TPE:4142), the current Beta is 0.0420 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adimmune (TPE:4142) Overvalued in 2026?

Based on GuruFocus' analysis, Adimmune stock appears to be undervalued. The current stock price of NT$16.80 is trading 33.9% below its estimated GF Value™ of NT$25.40. GuruFocus considers Adimmune to be Possible Value Trap.

Key valuation signals for TPE:4142:

  • Beta: 0.0420
  • GF Value™: NT$25.40 vs. price of NT$16.80 (33.9% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the TPE:4142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Adimmune Business Description

Address Tanxing Road, No. 3, Section 1, Tanzi District, Taichung City, TWN, 427003
Adimmune Corp is engaged in the research and development, processing, manufacturing, and trading of serum, vaccines, testing reagents, biologicals, and other bacterial fluids, as well as western medicines, animal medicines, chemicals, and feed additives. Its segments are separated by business as Adimmune Corporation, which generates maximum revenue and is engaged in the manufacturing of influenza vaccines with EU GMP and US FDA certificates in Taiwan. Its products include Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, and others, and Enimmune Corporation. The Group's revenue is mainly from the manufacturing and trading of vaccines, modern medicine products and testing reagents, as well as entrusted packing of vaccines.
55GF Score

Get the complete analysis for TPE:4142

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.80
Price
NT$25.40
GF Value